Novo Holdings, Catalent Reset Review Clock On $16.5B Deal
Novo Nordisk Foundation has given the Federal Trade Commission more time for an initial review of Novo Holdings' plan to acquire Catalent in a deal that values the pharmaceutical services company...To view the full article, register now.
Already a subscriber? Click here to view full article